Overview
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Description
Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.
Eligibility
Inclusion Criteria:
- Age > 18
- Histologically confirmed prostate cancer
- Gleason Score of index lesion ≤ 6 (3+3)
- Tumor stage: cT1-2a cN0 cM0
- Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3D-TPM-biopsy is mandatory before treatment.
- PSA ≤ 10/ng/ml
- Prostate volume < 60 m^3
- No distant metastasis
- Life expectancy > 10 years
- Informed consent
Exclusion Criteria:
- Tumor stage ≥ T2b
- Known metastasis: N+ and/or M1
- General anesthesia or peridural anesthesia is not possible
- Coagulation disorder